Seeking Alpha

Australia OKs Novartis' Bexsero meningitis vaccine

  • Novartis (NVS) receives approval in Australia for its Bexsero vaccine for protecting infants against MenB, a major cause of meningitis, adding to authorization in Europe. The drug is now licensed in over 30 countries.
  • In Australia, Bexsero is approved for children aged two months and older. (PR)
  • Meanwhile, Novartis has opened an internal probe into accusations by a former employee in China that she was instructed to bribe doctors by her manager in order to meet sales targets.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs